Biotech Drug Report Generated Jul 13, 2026

NEXLIZET

ESPR·Esperion Therapeutics, Inc.

NEUTRAL

Drug Impact Rating4/10

Trial Phase: Approved
Time to Market: Already approved and commercialized (since February 2020)
Why 4/10: NEXLIZET is an already-approved, commercially marketed drug (FDA approved Feb 2020, label expanded March 2024). There is no pending PDUFA or pivotal readout. The company was acquired by ARCHIMED and the merger closed on July 13, 2026, the equity is being delisted, eliminating any remaining binary catalyst for the stock.

Actionable Insight NEUTRAL

ESPR common stock has been acquired by ARCHIMED at $3.16/share with the deal closing July 13, 2026. Holders received one non-transferable Contingent Value Right (CVR) per share, entitling them to potential milestone payments tied to NEXLETOL/NEXLIZET U.S. net sales (starting 2027) and ENBUMYST (through 2030). There is no further tradeable equity vehicle, the stock will be delisted.

Price Chart

Loading chart...

Executive Summary

NEXLIZET (bempedoic acid + ezetimibe) is an FDA-approved non-statin cholesterol drug developed by Esperion Therapeutics. Approved in February 2020 for LDL-C lowering, it received a major label expansion in March 2024 to include cardiovascular risk reduction (preventing heart attacks and revascularization procedures) based on the CLEAR Outcomes trial. The company generated $403.1M in total revenue in FY2025 (up 21% YoY). However, Esperion was acquired by healthcare investment firm ARCHIMED in a ~$1.1B take-private deal that closed July 13, 2026, with shareholders receiving $3.16/share plus a non-tradeable Contingent Value Right. The stock is being delisted from Nasdaq.

How It Works

NEXLIZET is a once-daily combination pill with two different cholesterol-lowering drugs. Bempedoic acid reduces the liver's production of cholesterol by blocking an enzyme called ACL (working upstream of statins). Ezetimibe blocks the absorption of cholesterol from food in the intestine. Together they lower LDL ("bad") cholesterol through two complementary pathways. Unlike statins, bempedoic acid is only activated in the liver, so it typically avoids the muscle pain side effects that cause many patients to stop taking statins.

Trial Status

NEXLIZET was approved by the FDA on February 26, 2020 based on Phase 3 data. A major label expansion was approved in March 2024 based on the CLEAR Outcomes trial (nearly 14,000 patients, published NEJM March 2023), adding cardiovascular risk reduction to the indication. Pediatric Phase 3 studies are ongoing. Bempedoic acid received Class 1 recommendations in the 2026 ACC/AHA Dyslipidemia Guidelines.

The Two-Sided Case

▲ Bull Case5

NEXLIZET has strong clinical validation from the landmark CLEAR Outcomes trial (nearly 14,000 patients, published in NEJM), demonstrating cardiovascular event reduction in both primary and secondary prevention patients regardless of statin use.

The March 2024 FDA label expansion made NEXLIZET and NEXLETOL the first oral non-statins approved for CV risk reduction in both primary and secondary prevention, a major commercial expansion of the addressable patient population.

Bempedoic acid received multiple Class 1 recommendations in the 2026 ACC/AHA Dyslipidemia Guidelines, which should drive further adoption by clinicians.

Patent protection is robust, a settlement with Dr. Reddy's Laboratories pushes generic competition out to 2040, protecting the franchise for over a decade.

Company revenue grew 21% in FY2025 to $403.1M, with U.S. net product revenue up 38% YoY, demonstrating accelerating commercial uptake.

▼ Bear Case5

The acquisition by ARCHIMED closed on July 13, 2026, ESPR common stock is being delisted, eliminating any further trading opportunity in the equity; the CVR is non-transferable and cannot be traded.

CVR milestone payments are contingent on achieving U.S. net sales targets for NEXLIZET/NEXLETOL (2027) and ENBUMYST (up to 2030), creating binary risk that milestones may not be met, resulting in zero additional value beyond the $3.16/share.

NEXLIZET competes in a structurally price-sensitive market dominated by cheap generic statins and generic ezetimibe; branded pricing relies on payer formulary placement and prior-authorization hurdles.

Analyst consensus on ESPR before the deal closed was 0 Buy, 8 Hold, 3 Sell/Strong Sell, reflecting skepticism about the standalone commercial trajectory absent the acquisition premium.

Both Needham and HC Wainwright downgraded ESPR in May 2026 (to Hold and Neutral respectively) as the acquisition removed upside beyond the deal price.

Upcoming Catalysts

No further tradeable catalysts, the ARCHIMED acquisition closed on July 13, 2026. Future developments (milestone achievement under the CVR for NEXLIZET/NEXLETOL 2027 U.S. net sales targets) may affect CVR payout but are non-tradeable.
Ongoing pediatric Phase 3 studies and pipeline developments under ARCHIMED ownership are no longer relevant to public equity holders.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Esperion Therapeutics, Inc. 8-K ESPR ·Originating report

Sources · 8

Hover a chip for the title

1 esperion.com2 esperion.com3 goodwinlaw.com4 drugpatentwatch.com5 marketchameleon.com6 intellectia.ai7 sec.gov8 nexlizethcp.com